MPs Warn British Accords with President Trump are 'Built on Sand'.

Elected officials have raised concerns that the United Kingdom's negotiated accords with the US administration are "lacking a solid foundation." This comes after revelations that a so-called "milestone" deal on drug pricing, which pledges zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond broad headline terms outlined by government press releases.

Lacking Legal Footing

The deal on drug tariffs, promoted as a "significant" achievement, remains an "broad understanding" without a signed legal text. It has been highlighted that the press releases from the UK and US governments present the deal in divergent terms. The British version focuses on securing "zero per cent tariffs" as a unique achievement, while the American announcement concentrates on the expectation for the NHS to pay higher prices for new medications.

"We face a genuine possibility that the UK government has agreed to terms to increase medicine costs in return for little more than a assurance from President Trump," said David Henig, a trade expert. "It is documented he has a record of not keeping promises."

A Pattern of Unreliability

Anxieties have been heightened by Washington's move to pause the £31bn "tech prosperity deal", which was previously described as "a transformative pact" in the bilateral relationship. The US cited a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an initial accord have yet to be formally signed off by the US, despite a imminent January deadline. "We have been informed that that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have expressed concerns that the government's agreements with the US are flimsy and unreliable. One minister described the series of agreements as "built on sand," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, argued: "Perhaps most shocking than Trump's temper tantrums is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Ministry sources have sought to reduce the chances of the US reneging on the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been lobbying for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that volatility is a feature of dealing with the current US leadership. However, they argue that the UK has obtained tangible results for businesses, such as preferential tariff rates compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

However, problems have emerged in implementing the broader trade deal. Promised access for British beef have not materialized, and the commitment to "reduce steel tariffs to zero" has is still pending, with tariffs fixed at 25%.

Looking ahead, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "constructive" meetings between UK and US officials in Washington.